SCHEDULE: Kazia Therapeutics: Jorey Chernett Discloses Stake

Jorey Chernett has filed a Schedule 13G, reporting beneficial ownership of 2,114,649 American Depositary Shares in Kazia Therapeutics Ltd, representing 18.5% of the class.

Summary

• Jorey Chernett has filed an amendment to Schedule 13G, indicating a significant ownership stake in Kazia Therapeutics Ltd.
• The filing reports beneficial ownership of 2,114,649 American Depositary Shares (ADS).
• This ownership represents 18.5% of the total class of securities.
• The calculation of the percentage is based on 11,426,899 ADSs outstanding as of March 12, 2026, as per Kazia Therapeutics' Form F-3 filing on March 17, 2026.
• The reporting person, Jorey Chernett, has sole voting power and sole dispositive power over these shares.
• The filing is made under Rule 13d-1(b) and certifies that the securities were not acquired for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine ownership disclosure and does not contain operational or financial performance information.

Positives

• Jorey Chernett holds a substantial 18.5% stake in Kazia Therapeutics Ltd, indicating significant investor confidence or involvement.
• The reporting person has sole voting and dispositive power, suggesting direct control over their investment decisions.
• The filing confirms the total number of outstanding ADSs, providing clarity on the company's capital structure for this class of security.

Risks

• The filing does not explicitly mention any risks, as it is a disclosure of ownership rather than a business update.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are crucial for tracking significant institutional and individual ownership changes in publicly traded companies, providing transparency for investors regarding major stakeholders.

Stakeholder Impact

• Shareholders: Provides transparency on a significant ownership stake, which can influence market perception and potential future corporate actions.
• Management: The disclosure highlights a substantial shareholder, which may necessitate engagement or consideration of their interests.

Key Dates

Keywords

Kazia Therapeutics, Schedule 13G, Jorey Chernett, American Depositary Shares, Ownership, SEC Filing, Beneficial Ownership, Form F-3, Securities Exchange Act